United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x) - polymyxin b 10000 [usp'u] in 1 ml - polymyxin b sulfate and trimethoprim ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenzae and pseudomonas aeruginosa.1 1 efficacy for this organism in this organ system was studied in fewer than 10 infections. polymyxin b sulfate and trimethoprim ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

unit dose services - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - polymyxin b 10000 [usp'u] in 1 ml - polymyxin b sulfate and trimethoprim ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenzae and pseudomonas aeruginosa. ** **efficacy for this organism in this organ system was studied in fewer than 10 infections. polymyxin b sulfate and trimethoprim ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x) - polymyxin b 10000 [usp'u] in 1 ml - polymyxin b sulfate and trimethoprim ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenzae and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. polymyxin b sulfate and trimethoprim ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x) - polymyxin b 10000 [usp'u] in 1 ml - polymyxin b sulfate and trimethoprim ophthalmic solution, usp is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenzae and pseudomonas aeruginosa.* *efficacy for this organism in this organ system was studied in fewer than 10 infections. polymyxin b sulfate and trimethoprim ophthalmic solution, usp is contraindicated in patients with known hypersensivitity to any of its components.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x) - polymyxin b 10000 [usp'u] in 1 ml - polymyxin b sulfate and trimethoprim ophthalmic solution, usp is a sterile antimicrobial solution for topical ophthalmic use. it has ph of 4.0 to 5.5 and osmolality of 270 to 310 mosm/kg. chemical names: trimethoprim sulfate, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine sulfate, is a white, odorless, crystalline powder with a molecular weight of 678.72 and the following structural formula: c28 h38 n8 o10 s mol. wt. 678.72 polymyxin b sulfate is the sulfate salt of polymyxin b1 and b2 which are produced by the growth of bacillus polymyxa  (prazmowski) migula (fam. bacillaceae). it has a potency of not less than 6,000 polymyxin b units per mg, calculated on an anhydrous basis. the structural formula is: each ml contains: actives: polymyxin b sulfate equal to 10,000 polymyxin b units, trimethoprim sulfate (equivalent to trimethoprim 1 mg); inactives: purified water, sodium chloride. sulfuric

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals nj, llc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.3 mg

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin sublingual tablets, usp are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. nitroglycerin is contraindicated in patients who are allergic to it. sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin. administration of nitroglycerin sublingual tablets is contraindicated in patients who are using a phosphodiesterase-5 (pde-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates. do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitrostat is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. 4.1 pde-5-inhibitors and sgc-stimulators do not use nitrostat in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitrostat in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. 4.2 severe anemia nitrostat is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 increased intracranial pressure nitrostat may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 hypersensitivity nitro